SMS Pharma to deduct TDS on Rs. 0.40/share final dividend for FY26
SMS Pharmaceuticals Limited recommended a final dividend of ₹0.40 per equity share for FY25-26. The AGM to approve this dividend is on September 23, 2026. The record date is September 16, 2026. Shareholders must submit TDS-related documents by September 9, 2026, to avail benefits.
This is a procedural announcement detailing the process of dividend distribution and TDS. It does not involve significant corporate actions, financial results, or strategic shifts that would materially impact the company's stock or business operations.
The announcement is a routine communication regarding dividend payout procedures and tax implications, which is standard for companies. It does not contain any new business developments or financial performance indicators that would suggest a positive or negative sentiment.
SMS Pharmaceuticals Limited has issued a communication to its shareholders regarding the deduction of Tax Deducted at Source (TDS) on the final dividend for the financial year 2025-26. The Board of Directors recommended a final dividend of ₹0.40 per equity share of face value ₹1 each, subject to shareholder approval at the 38th Annual General Meeting (AGM).
The AGM is scheduled to be held on Wednesday, 23rd September, 2026. The company has fixed Wednesday, 16th September, 2026, as the 'Record Date' to determine the entitlement of members to this final dividend. The dividend, if approved, will be paid after 23rd September, 2026, after deducting applicable taxes at source.
The announcement details the provisions of the Income-tax Act, 2025, concerning TDS on dividends. It outlines specific tax deduction rates and exemption applicability for both resident and non-resident shareholders, including requirements for submitting forms like Form 121 (Part A) and Tax Residence Certificates (TRC) for beneficial tax treatment. Shareholders are advised to submit necessary documents by Wednesday, 09th September, 2026, through a designated portal or to the Registrar and Transfer Agent (RTA), Aarthi Consultants Private Limited. The company also emphasizes the importance of updating bank account details for electronic dividend payments and compliance with SEBI regulations.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.